Claudia I Guevara
About Claudia I Guevara
Claudia I Guevara is a Senior Associate Scientist at Kite Pharma, where she has worked since 2017, specializing in the development of novel cancer therapies. With over 20 years of experience in Immuno-Oncology, she has a strong background in CAR T, TCRs, bi-specific molecules, and therapeutic antibodies.
Work at Kite Pharma
Claudia I Guevara has been employed at Kite Pharma since 2017. She initially joined as an Associate Scientist and has progressed to the role of Senior Associate Scientist in 2020. Her work at Kite Pharma focuses on the development and validation of CAR T therapies, T cell receptors (TCRs), bi-specific molecules, and therapeutic antibodies/antibody-drug conjugates (ADCs). Located in Santa Monica, California, her contributions are integral to the company's efforts in advancing novel cancer therapies.
Education and Expertise
Claudia I Guevara earned her Bachelor of Arts degree in Integrative Biology from the University of California, Berkeley, where she studied from 1992 to 1996. She possesses over 20 years of industry experience in Immuno-Oncology, specializing in the development of innovative cancer therapies. Her expertise includes the development and validation of CAR T therapies, TCRs, bi-specific molecules, and therapeutic antibodies/ADCs.
Background
Before joining Kite Pharma, Claudia I Guevara worked at Peregrine Pharmaceuticals as a Research Scientist from 2004 to 2009. Her role there contributed to her extensive experience in the field of Immuno-Oncology. Earlier in her career, she served as a Lab Manager and Research Associate at the Hillary C.M. Nelson Lab at UC Berkeley from 1994 to 1998, where she gained foundational skills in research and laboratory management.
Professional Experience
Claudia I Guevara has accumulated significant professional experience in the biotechnology and pharmaceutical industries. Her tenure at Kite Pharma, spanning over seven years, is complemented by her five years at Peregrine Pharmaceuticals and four years at UC Berkeley. This diverse background has equipped her with a comprehensive understanding of cancer research and therapeutic development.